SIGN UP FOR UPDATES!
Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
ENGLEMED
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BOOKS AND GIFTS THIS WAY!
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
SEARCH THIS SITE
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
FreeDigitalPhotos
www.freedigitalphotos.net
FreeWebPhotos
www.freewebphoto.com
FROM OUR NEWS FEEDS
Asymptomatic Covid-19 infection could be higher than thought
Thurs May 28th - The number of people with Covid-19 who are asymptomatic could be much higher than previously thought, according to an analysis of a cruise ship outbreak published today. More
DCIS doubles future breast cancer risk
Thurs May 28th - Women diagnosed with ductal carcinoma in situ during breast screening face an increased risk of developing breast cancer later in life, a study published today says. More
RECENT COMMENTS
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote:
https://epidemicj17.imascientist.org.uk/2017/06/21... on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
On 12/03/2017 Steph wrote:
The photo you have paired with this article is its... on 'Fat shaming' limits...
OTHER NEWS FEEDS OF INTEREST
ENGLEMED HEALTH NEWS

Aggressive LDL reduction backed at conference

Tuesday August 29th, 2017

Aggressive reduction of LDL cholesterol levels is safe - and reduces cardiovascular events, a major European conference has been told.

Researchers revealed the latest findings from a trial of a new lipid-lowering drug at the conference of the European Society of Cardiology in Barcelona, Spain.

Nearly 26,000 patients were included in the analysis by US-based researchers. Patients in the FOURIER study were randomised to receive a monoclonal antibody, evolocumab, as well as background statin therapy.

Early results suggested the monoclonal antibody was effective.

The latest analysis showed that cardiovascular events declined "steadily" with levels of LDL cholesterol, the researchers reported.

About 10% of patients - 2,669 - achieved the lowest LDL levels.

According to the research, patients who achieved LDL levels less than 0.26 mmol/L were 40% less likely to experience cardiovascular events than those achieving a level of 2.6 mmol/L.

The researchers conducted further tests on some 1,154 patients to check for cognitive impairment linked to the treatment or to LDL-lowering. They reported no adverse events.

The findings were also being reported in The Lancet today.

Researcher Dr Robert Giugliano, from Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA, said it suggested that "a lower LDL-C target - far below current guidelines - can safely be considered to further reduce the risk of recurrent cardiovascular events in high risk patients.”

He added: "Our findings demonstrate that there is essentially no floor effect, and that lower levels translated to a greater reduction in risk. Among high-risk patients, achieving a LDL cholesterol level far below the most common treatment target of 1.8 mmol/L can further reduce the risk for an adverse cardiovascular event, with no major safety concerns."

Abstract: Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Tags: Diet & Food | Europe | Heart Health | North America | Pharmaceuticals

Printer friendly page Printer friendly page

Comment on this article:

Name:
Email:
Comment:
<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)
CATEGORIES